Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for MK-3475

5 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCMD1605

    03/28/2017

    Phase 1/2a Study of Double-Immune Suppression Blockade by Combining a CSF1R Inhibitor (PLX3397) with an Anti-PD-1 Antibody (Pembrolizumab) to Treat Advanced Melanoma and Other Solid Tumors

    Treatment

    ECOGBRES1418

    03/17/2017

    A Randomized, Phase III Trial to Evaluate The Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN+) After Neoadjuvant Chemotherapy

    Treatment

    VICCMD1649

    12/14/2016

    A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer and Melanoma

    Treatment

    VICCPED1620

    12/08/2016

    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma

    Treatment

    ECOGMELS1404

    12/01/2015

    A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma


    Print this page for your doctor